Successfully achieved complete separation and miniaturization of the main drug! We are developing a combination product as a nucleated tablet.
We will introduce our representative formulation technology along with specific examples. The combination product of a proton pump inhibitor (a treatment for peptic ulcers) and low-dose aspirin has been developed and launched as a formulation containing 100mg of aspirin and 15mg of proton pump inhibitor per tablet. Its usefulness, including formulation characteristics, has been highly evaluated. We respond to all requests related to CMC from the early stages of development to application. Please feel free to contact us when needed. 【Features】 ■ Complete separation to avoid interactions between active ingredients ■ Maintenance of the formulation system equivalent to that of a single agent (BE) ■ Miniaturization while maintaining formulation strength *For more details, please refer to the PDF materials or feel free to contact us.
Inquire About This Product
basic information
For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Our company is a pharmaceutical CMC research and development contract company that spun out from the CMC research division of Takeda Pharmaceutical Company Limited in July 2017. We support excellent pharmaceutical development as experts in CMC research. Our research team consists of experts with extensive experience and achievements in process chemistry, formulation research and development, and analytical testing development related to CMC research. We provide high-level services and solutions tailored to our customers' needs across each process from the early stages of pharmaceutical development to application, while flexibly collaborating. We have established a collaborative system with partner companies, enabling us to offer a one-stop service. Please utilize us as a platform for your pharmaceutical development.